Compound class:
Synthetic organic
Comment: The structure for tacaciclib was obtained from proposed INN list 129 (August 2023), where it is described as cyclin-dependent kinase inhibitor and antineoplastic agent. The structure is calimed in patent WO2022130304A1, for potential to treat cancer or other proliferative diseases that are mediated by CDK7 [1]. Interogation of online information suggests that this compound may be XL102 (formerly AUR102), an orally bioavailable covalent CDK7 inhibitor that was acquired by Exelixis, from Aurigene, in late 2020.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide |
Database Links | |
CAS Registry No. | 2768774-66-7 (source: WHO INN record) |
GtoPdb PubChem SID | 485206001 |
PubChem CID | 164533260 |
Search Google for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |
Search Google for chemicals with the same backbone | CVAXNGIXLUILFO |
UniChem Compound Search for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |